The novel benzimidazole derivative<scp>BRP</scp>‐7 inhibits leukotriene biosynthesis<i>in vitro</i>and<i>in vivo</i>by targeting 5‐lipoxygenase‐activating protein (<scp>FLAP</scp>)

Abstract

BRP-7 potently suppresses LT biosynthesis by interacting with FLAP and exhibits anti-inflammatory effectiveness in vivo, with promising potential for further development.